J&J Resumes all Clinical Trial of its COVID-19 Vaccine in the EU

Shots:

  • J&J has resumed recruitment, enrolment, and vaccination in all studies of its COVID-19 vaccine across the EU, after a temporary pause. Trials in the US, South Africa, and some Latin American countries are already ongoing
  • Clinical trials to be resumed are the P-IIa studies in Germany, the Netherlands, and Spain and P-I/IIa study in Belgium
  • The company is preparing for the initiation of a second P-III study of the COVID-19 vaccine candidate. The trial will evaluate a 2-dose regimen and is anticipated to start later this month across the EU. The study follows positive interim results of the P-I/IIa study, showing the safety profile and immunogenicity of the COVID-19 vaccine was supportive of further development

Click here ­to­ read full press release/ article | Ref: Janssen | Image: Law.com

The post J&J Resumes all Clinical Trial of its COVID-19 Vaccine in the EU first appeared on PharmaShots.